RDY
Dr. Reddy’s Laboratories Ltd
12.30$
+0.6%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 62.7% | 64.0% | 64.0% | 64.8% | 53.3% | 52.6% | 50.7% | 51.9% | 51.6% | 52.9% | 52.1% | 52.0% | |
| 3.9% | 2.0% | 1.8% | 1.2% | 2.4% | 2.6% | 3.0% | 1.7% | 1.8% | 3.3% | 2.7% | 1.9% | |
| 19.5% | 19.4% | 21.0% | 22.8% | 13.5% | 12.3% | 11.7% | 12.8% | 12.9% | 14.7% | 15.2% | 14.2% | |
| 25.8% | 25.8% | 24.6% | 19.5% | 22.1% | 23.2% | 22.3% | 22.2% | 22.3% | 22.1% | 17.5% | 21.6% | |
| 16.3% | 16.3% | 16.4% | 16.5% | 15.5% | 14.9% | 14.4% | 14.6% | 14.0% | 14.0% | 13.2% | 14.0% | |
| 20.2% | – | 19.6% | – | 18.4% | – | 19.7% | – | 20.5% | – | – | – | |
| 1.2% | 1.1% | 1.1% | 1.0% | 2.5% | 2.5% | 2.4% | 2.3% | 2.3% | 2.2% | 2.2% | 2.2% | |
| 10.7% | 9.9% | 9.5% | 8.9% | 19.8% | 19.3% | 19.6% | 18.4% | 18.6% | 18.2% | 18.1% | 18.0% | |
| 27.1% | 28.2% | 27.6% | 29.1% | 33.6% | 33.2% | 31.6% | 31.9% | 33.2% | 33.2% | 34.3% | 32.8% | |
| 24.3% | 25.1% | 24.8% | 25.4% | 27.7% | 27.4% | 26.4% | 27.4% | 27.8% | 28.1% | 28.9% | 27.3% | |
| 2.1% | 3.7% | 3.6% | 5.9% | 8.8% | 9.0% | 7.9% | 8.4% | 8.7% | 10.0% | 11.2% | 10.4% | |
| 8.8% | 8.3% | 5.6% | 8.2% | 7.7% | 7.5% | 4.1% | 7.2% | 7.4% | 7.2% | 5.8% | 6.5% | |
| 1.1% | 1.0% | 1.0% | 0.9% | 0.8% | 0.8% | 0.8% | – | 0.0% | – | 2.1% | – | |
| 72.9% | 71.8% | 72.4% | 70.9% | 65.5% | 66.0% | 67.6% | 67.4% | 66.1% | 66.2% | 65.1% | 66.6% | |
| 68.6% | 67.6% | 68.5% | 67.2% | 61.2% | 62.2% | 64.1% | 63.5% | 62.3% | 62.1% | 60.8% | 62.0% | |
| 0.2% | 0.0% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.2% | 0.1% | 0.1% | 0.1% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.